Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA developing off-label policy

FDA staff are working on a draft guidance outlining procedures for drug sponsors to disseminate information about off-label uses of drugs.

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE